Know Cancer

forgot password

Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

Phase 1
18 Years
Open (Enrolling)
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection.

Thank you

Trial Information

Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

Inclusion Criteria:

- Histologically or cytologically confirmed solid cancer of any pathology or
adenocarcinoma of the pancreas with evidence of locally advanced (non resectable
Stage II or III) or metastatic disease (Stage IV).

- For advanced solid cancer patients (part A), who may have received previous
chemotherapy or radiation therapy, but must be amenable for a gemcitabine treatment
according to the discretion of the principal investigator.

- For pancreatic cancer patients who may have received previous chemotherapy against
pancreatic cancer or local radiation for palliation if the irradiated area was not
the only source of measurable or assessable disease.

- Karnofsky performance status 60-100% (ECOG performance status ≤2).

- Patients aged >/= 18 years.

- Patients must have at least one uni-dimensionally measurable lesion by computed
tomography as defined by RECIST V1.1 criteria. This lesion must not have been
irradiated during previous treatments.

- All acute toxic effects (excluding alopecia) of any prior therapy (including surgery,
radiation therapy, chemotherapy) must have resolved to National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v3.0) Grade ≤ 1.

- Sufficient hematologic, liver and renal function:

- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L, platelets ≥ 100 x 10^9/L,
haemoglobin (Hb) ≥ 9.5 g/dl.

- Alkaline phosphatase (AP), alanine aminotransferase (ALT) and or aspartate
aminotransferase ≤ 3 x upper limit of reference range (ULN), and total bilirubin
≤ 2.0 mg/gL unless liver involvement by the tumor, in which case the
transaminase levels could be up to 5 x ULN.

- Creatinine ≤ 1.5 ULN or 24 h creatinine clearance ≥ 50 mL/min.

- Life expectancy of at least 12 weeks.

- Documented negative test for human immunodeficiency virus.

- Negative serum pregnancy test for females of childbearing potential within 14 days of
starting treatment.

- If of childbearing potential, agreement must be made to use adequate contraceptive
methods (e.g., oral contraceptives, condoms, or other adequate barrier controls,
intrauterine contraceptive devices, or sterilization) beginning at the screening
visit and continuing until 3 months following last treatment with study drug.

- Evidence of a personally signed and dated Ethics Committee-approved Informed Consent
indicating that the patient (or legally acceptable representative) has been informed
of all pertinent aspects of the study.

- Willingness and ability to comply with the scheduled visits, treatment plan,
laboratory tests and other study procedures.

Exclusion Criteria:

- Presence of active infections (e.g. requiring antibiotic therapy) or other severe
concurrent disease, which, in the opinion of the investigator, would place the
patient at undue risk or interfere with the study.

- Presence of known brain metastases. If patient is symptomatic, negative CT scan
within two months before study beginning is required. However, presence of controlled
brain metastases (i.e., evaluated as SD or PR after radiotherapy) is allowed.

- Previous or concurrent cancer that is distinct in primary site or histology from the
cancer being evaluated in this study, or any cancer curatively treated ≥ 2 yeast
prior to study entry, except cervical carcinoma in situ, treated basal cell
carcinoma, superficial bladder tumours (TA, TIs &TI).

- History of chronic hepatitis B or C, or chronic active hepatitis or active autoimmune

- History within the last year of acute or subacute coronary syndromes including
myocardial infarction, unstable or severe stable angina pectoris.

- Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).

- Irreversible cardiac arrhythmias requiring permanent medication.

- Uncontrolled hypertension.

- Ischemic peripheral vascular disease (Grade IIb-IV).

- Severe rheumatoid arthritis.

- Severe diabetic retinopathy.

- History of allograft or stem cell transplantation

- Major trauma including surgery within 4 weeks of administration of study treatment.

- Known history of allergy to IL2, gemcitabine, or other intravenously administered
human proteins/peptides/antibodies.

- Pregnancy or breast feeding. Female patient must agree to use effective
contraception, or be surgically sterile or postmenopausal. The definition of
effective contraception will be based on the judgment of the principal investigator
or a designated associate.

- Chemotherapy (standard or experimental) or radiation therapy within 4 weeks of the
administration of study treatment.

- Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6
weeks before administration of study treatment.

- Growth factors or immunomodulatory agents within 7 days of the administration of
study treatment.

- Patient requires or is taking corticosteroids or other immunosuppressant drugs on a
long-term basis. Limited use of corticosteroids to treat or prevent acute
hypersensitivity reactions is not considered an exclusion criterion. A maximum dose
per day of 5 mg prednisone (or equivalent), when it is meant to address cancer
symptoms (e.g., pain, dyspnoea, lack of appetite), is allowed. A suspected presence
of chronic inflammatory disease has to be considered an exclusion criterion.

- Any conditions that in the opinion of the investigator could hamper compliance with
the study protocol.

- Persons who are interned in Institutions by Judiciary or other Authorities

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum tolerated dose and the preliminary tolerability profile.

Outcome Description:

Establishment of the maximum tolerated dose (MTD) and the preliminary tolerability profile of L19IL2 and gemcitabine including the recommended phase II doses (RD) when used in combination.

Outcome Time Frame:

49 days

Safety Issue:



Italy: National Institute of Health

Study ID:




Start Date:

June 2007

Completion Date:

December 2014

Related Keywords:

  • Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection.
  • Interleukin, IL2, Gemcitabine, monoclonal, antibody, cytokine, tumour targeting, dose finding, fusion protein, Pancreatic cancer,
  • L19
  • Pancreatic Neoplasms